Acceleron's cancer drug dalantercept enters midstage development

02/7/2013 | American City Business Journals

Acceleron Pharma initiated two midstage trials to assess the efficacy of its experimental drug dalantercept, or ACE-041, in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer, and with Pfizer's Inlyta, or axitinib, in patients with metastatic renal cell carcinoma.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care